Podcasts about Waxman

Det er etterhvert velkjent at HL-Senteret motarbeider og ødelegger for jøder i Norge, men det nylige eventet med Omer Bartov var et et nytt lavmål. Bartov ble invitert til å holde foredrag, og til panelsamtale om temaet "Gaza after Holocaust", mer info her: https://www.uio.no/english/research/domus-bibliotheca/events/2026/holocaust-memorialHL-senteret og Universitetet i Oslo inviterte den 3. juni 2026 til samtale ved Scene Domus Bibliotheca med Bartov, om fremtiden for Holocaust-minnet. Samtalen ble ledet av Peder Nustad, leder for Dembra (HL-senteret). Nikolai Melamed Kleivan, journalist i Morgenbladet deltok i panelet.Nina Grünfeld, filmskaper, forfatter og professor ved Universitetet i Innlandet deltok i panelet.Arrangementet var en del av serien «I krigens skygge – veien videre», et samarbeid mellom HL-senteret og Universitetet i Oslo, og fikk støtte fra Fritt Ord.Om arrangementet skriver HL-Senteret selv følgende:"Minnekulturen rundt Holocaust har blitt et referansepunkt i arbeidet mot rasisme, menneskerettighetsbrudd og massevold. Med krigen i Gaza har Holocaust-minnet i økende grad blitt trukket inn i samtidens politiske debatter. Vi spør hvordan dette påvirker fagfeltets troverdighet og brede offentlige oppslutning."Kritikk av opplegget:- Bare det å sammenligne Gaza med Holocaust er forkastelig.- HL-senterets opplegg var både irrelevant for norsk kontekst og tendensiøst. - Paneldesignet var ensidig og testet ikke engang Bartovs hovedpåstand. - Folkemordspåstanden bygges ikke juridisk. - Ødeleggelse leses direkte som intensjon. - Hamas' rolle og Israels handlingsrom underbehandles.- “Nowhere to go”-argumentet forenkler Egypt/Rafah og årsaksskjeden.- Tittelen gjør Holocaust-minne til forklaringsramme før spørsmålet er prøvd.- Fallback-logikken gjør forbrytelseskategorier til forhandlingsnivåer; diskursen glir ofte slik: hvis ikke folkemord, så forbrytelser mot menneskeheten. Hvis ikke forbrytelser mot menneskeheten, så krigsforbrytelser. Hvis ikke krigsforbrytelser, så etnisk rensing. Hvis ikke det, så kollektiv avstraffelse. Dette er metodisk svakt.- Bartov glir mellom rettsanvendelse og begrepspolitikk.Referanser:Bartov, Omer. “I'm a Genocide Scholar. I Know It When I See It.” New York Times, 15. juli 2025.Waxman, Dov. “On ‘A Textbook Case of Genocide.'” Jewish Currents, 2023.Goda, Norman J.W. “The Genocide Libel: How the World Has Charged Israel with Genocide.” Institute for the Study of Contemporary Antisemitism, Indiana University, 2025.Goda, Norman J.W. og Jeffrey Herf. “Why It's Wrong to Call Israel's War in Gaza a ‘Genocide.'” Washington Post, 3. juni 2025.Satloff, Robert. “A Charade in Academic Garb.” Washington Institute for Near East Policy, 2. september 2025.Moses, A. Dirk. The Problems of Genocide: Permanent Security and the Language of Transgression. Cambridge University Press, 2021.Convention on the Prevention and Punishment of the Crime of Genocide, artikkel II.Rome Statute of the International Criminal Court, artikkel 7.ICRC Customary International Humanitarian Law, Rule 97: Human Shields.► Skaff deg boken min: Frykt og Stillhet - jødiske stemmer i Norge etter 7. oktober. Bestill her:  https://bok.norli.no/frykt-og-stillhet► STØTT ARBEIDET PÅ VIPPSOm du ønsker å støtte arbeidet med denne podcasten, kan du bidra med et stort eller lite beløp, etter eget ønske. All støtte settes pris på, og du bidrar til arbeidet med å lage flere episoder. Bruk Vippsnummer: #823278►  ⁠BLI ⁠⁠⁠⁠MEDLEM⁠⁠⁠⁠⁠ Fremover vil de som er støttemedlemmer få tilgang til episodene først. Da støtter du podcasten med det samme som prisen av en kaffe hver måned. Setter stor pris på om du blir støttemedlem. Tusen takk.► Annonsere på Henrik Beckheim Podcast?Send en mail til post@henrikbeckheim.no ► MERCH: Kjøp klær, kopper, capser og mer: https://henrikbeckheim.com/store► Linker:⁠⁠Youtube⁠⁠ | ⁠⁠Nettside⁠⁠ | ⁠⁠TikTok⁠⁠ | ⁠⁠Instagram⁠⁠ | Podimo | ⁠⁠Facebook⁠⁠ | ⁠⁠Apple

In this episode, Emily Capodilupo sits down with gerontologist, leadership coach, and author of The Middlescence Manifesto Barbara Waxman to explore the powerful idea of “middlescence” — a transformative stage of life between young and late adulthood. Together, they unpack why midlife isn't a crisis, but an opportunity for reinvention, alignment, and growth. Listeners will learn how mindset, purpose, relationships, and joy directly impact an individual's healthspan and longevity. Emily and Barbara share the best strategy to use wearable data as a tool for self-awareness rather than self-judgment. This conversation is full of practical insights on flourishing at every age, redefining success, and building a life that feels both healthy and deeply meaningful.(00:33) Intro to Barbara Waxman(01:00) What is Middlescence? How To Redefine Midlife(03:20) Addressing This New Life Stage & Creating Change(06:22) Coaching People Through Midlife(08:15) Debunking The Concept of the Midlife Crisis(09:57) Key Lifestyle Shifts From a Life Coach(12:23) 7 Lifestyle Levers: Where People Start To Prepare for Middlescence(17:21) Reframing Longevity: Live Better, Not Just Longer(19:37) How Barbara Uses WHOOP Data In Her Practice(25:54) Lifestyle Considerations For A Healthy Life Beyond Longevity & Healthspan(34:51) How People in Their 20s, 30s, 40s,and 50s Can Increase LongevityFollow Barbara Waxman:WebsiteLinkedInSupport the showFollow WHOOP:Sign up for WHOOP Advanced LabsTrial WHOOP for Freewww.whoop.comInstagramTikTokYouTubeXFacebookLinkedInFollow Will Ahmed:InstagramXLinkedInFollow Kristen Holmes:InstagramLinkedInFollow Emily Capodilupo:LinkedIn 

C'est à l'occasion de la sortie de son nouvel album, intitulé Exile to Hollywood et consacré aux compositeurs de l'âge d'or du cinéma américain, que nous recevons Isabelle Durin, violoniste passionnée de musique de film, pour une conversation à bâtons rompus autour de Steiner, Waxman, Rózsa, Tiomkin et bien d'autres.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Jordan Waxman, founder and managing partner at Nucleus Advisors of Hightower Advisors, discusses how his boutique firm serves entrepreneurs, athletes, artists, and executives through highly personalized, values-based wealth planning. From pre-liquidity event strategy to multi-generational legacy conversations, Waxman shares how Nucleus' trademarked “withness” philosophy helps clients navigate complex financial and family dynamics with deeper connection and intentionality.

Alan Waxman’s Sixth Street Partners has a deep conviction in sports. Over the past five years, Alan and his firm have taken a minority stake in teams in most major professional leagues, including: the Boston Celtics, the San Antonio Spurs, the San Francisco Giants and FC Barcelona. In 2024, Sixth Street became the first investment fund to take a controlling interest in an American pro team with the NWSL’s Bay FC. And as of September 2025, Sixth Street owns a 3% stake in one of the biggest names in sports- the New England Patriots. In this episode of The Deal, Alex and Jason sit down with Alan live at Bloomberg Invest. Alan tells the story of getting the call from Robert Kraft and why Sixth Street is one of only a handful of PE firms approved to invest in the NFL. He also shares his view on international growth opportunities in the NBA, why a historic NWSL expansion fee paid off and how far away we are from institutional capital taking a controlling stake in an NFL or NBA team. Finally, Alex and Alan give their takes on how to “fix” professional baseball. You can also watch this interview on YouTube.See omnystudio.com/listener for privacy information.

In September 1982, seven people in the Chicago area died after taking cyanide-laced Extra Strength Tylenol capsules, sparking one of the most infamous unsolved murder cases in American history. The victims ranged from a 12-year-old girl to parents and working professionals, all unknowingly poisoned after using a trusted over-the-counter medication. As panic spread, Johnson & Johnson issued a nationwide recall and introduced tamper-proof packaging that permanently changed the pharmaceutical industry. Investigators pursued multiple suspects over the years, but no one has ever been charged with the murders. In this episode, we examine the victims, the investigation, the leading theories, and the lasting impact of the Tylenol murders. Sources:  Ganger, Brigitte; “Remembering the Victims of the Chicago Tylenol Murders”; Beyond the Dash; Sept 29, 2021; https://beyondthedash.com/blog/remembering/remembering-the-victims-chicago-tylenol-murders/7360; accessed May 9, 2026.  Petros, Michael; “People, politics and poison: the Tylenol® murders revisited forty years later”; The University of Illinois Chicago; May 31, 2022; https://publichealth.uic.edu/news-stories/people-politics-and-poison-the-tylenol-murders-revisited-forty-years-later/; accessed May 9, 2026.   Simpson, Michael Lee;  “POISONED PILL My cop dad's deathbed confession to the 7 unsolved Tylenol murders tore me apart – he left key evidence for me to find”; The U.S. Sun; Sept 28, 2025; https://www.the-sun.com/news/15253060/tylenol-murders-chicago-cops-deathbed-confession/; accessed May 9, 2026.   Waxman, Olivia B.;  Netflix's Tylenol Murders Doc Dives Into a Chilling Unsolved Crime; Time; May 26, 2025; https://time.com/7287680/tylenol-murders-documentary-netflix/; accessed May 10, 2026.   “Who Committed the Tylenol Murders? After More Than 40 Years, the Case Remains Unsolved.”; WTTW; https://www.wttw.com/chicago-stories/inside-the-tylenol-murders/who-committed-the-tylenol-murders; accessed May 10, 2026.  Clark, Josh; Dove, Laurie L.; “10 Notable Copycat Killers”; How Stuff Works; June 7, 2024; https://people.howstuffworks.com/5-copycat-killers.htm; accessed May 10, 2026.  “Johnson & Johnson's Tylenol Crisis: A Lesson in Ethical Crisis Management”;  Journalism.University; Jan 24, 2026; https://journalism.university/media-ethics-and-laws/tylenol-crisis-ethical-management-lessons/; accessed May 10, 2026.   

My guest today is Alan Waxman, co-founder and CEO of Sixth Street, a $130B global investment firm. Private credit is one of the most discussed topics in markets right now, and there is a lot to make sense of. The current discourse is almost entirely focused on symptoms. Alan Waxman has spent the time diagnosing the root cause. Alan thinks about the financial system the way a historian would, studying the incentives, guardrails, and market structure that determine how things play out. In this conversation, he traces the evolution of American finance from the 1929 crash through Glass-Steagall, the GFC, and Basel III to explain how we arrived at what he calls the factory model, the industrialization of liability-gathering and asset deployment that he believes is the root cause of everything happening in private markets today. This is my second conversation with Alan, our first one is one of my favorites from last year.  For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠.  ----- This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠Ramp⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠ramp.com/invest⁠ to sign up for free and get a $250 welcome bonus. ----- This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Vanta. Trusted by thousands of businesses, Vanta continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit vanta.com/invest.  ----- This episode is brought to you by ⁠WorkOS⁠. WorkOS is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit ⁠WorkOS.com⁠ to transform your application into an enterprise-ready solution in minutes, not months. ----- Rogo is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ridgeline⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ridgelineapps.com. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps (00:00:00) Welcome to Invest Like The Best (00:02:43) Intro: Alan Waxman (00:04:35) Financial System Guardrails & Incentives (00:05:56) System 1: Pre-1933 to 1999 (00:07:39) Glass-Steagall Legislation (00:10:46) Deregulation & Rise of System 2 (00:12:27) Leverage, GFC, and System 2's Collapse (00:14:25) Basel III, Dodd-Frank, and System 3 (00:15:32) Why System 3 Could Be the Best Ever (00:19:04) Behavioral Shifts Starting in 2018 (00:19:52) The Factory Model (00:24:33) Acceleration of Factory Model (00:28:25) FRE Multiples and GP Incentives (00:34:59) Wealth Channel & Asset-Liability Mismatches (00:36:15) Why This Won't be the Next GFC (00:45:31) AI, Creative Destruction & Opportunity  (00:49:35) Alan's One-Sheet Brain System (00:55:01) Lessons by Decade: Hui (00:59:28) Face the Tiger

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

In 1982, seven people died after taking doses of Extra Strength Tylenol, leading to a full-blown and safety standards for over-the-counter meds. To this day, the murders remain unsolved. Strange Country cohosts Beth and Kelly discuss this 1982 mystery and its possible suspects while Beth mispronounces "business ethics" because that's not really a thing. Theme music: Big White Lie by A Cast of Thousands. Cite your sources:  Bergmann, Joy. "A Bitter Pill." Chicago Reader, 2 Nov. 2000, https://chicagoreader.com/news/a-bitter-pill/. Accessed 22 Mar. 2026. Cold Case: The Tylenol Murders. Directed by Yotam Guendelman and Ari Pines, Netflix, 2025. Accessed 22 Mar. 2026. Harris, Gardiner. No More Tears: The Dark Secrets of Johnson & Johnson. Random House, 2025. Locke, Taylor. "Tylenol Orders in Pregnant People Plummeted after Trump Falsely Linked the Drug to Autism." Scientific American, 12 Mar. 2026, www.scientificamerican.com/article/tylenol-orders-in-pregnant-people-plummeted-after-trump-falsely-linked-the/. Accessed 23 Mar. 2026. "Searching for Tylenol Murder Suspects." Thirteen / PBS, https://www.thirteen.org/programs/chicago-stories/searching-for-tylenol-murder-suspects-iamsis/. Accessed 22 Mar. 2026. Waxman, Olivia B. "The True Story Behind Cold Case: The Tylenol Murders." Time, 26 May 2025, https://time.com/7287680/tylenol-murders-documentary-netflix/. Accessed 22 Mar. 2026. "Who Committed the Tylenol Murders? After More Than 40 Years, the Case Remains Unsolved." WTTW Chicago, https://www.wttw.com/chicago-stories/inside-the-tylenol-murders/who-committed-the-tylenol-murders. Accessed 22 Mar. 2026. Winny, Annalies. "The Evidence on Tylenol and Autism." Johns Hopkins Bloomberg School of Public Health, 7 October 2025, https://publichealth.jhu.edu/2025/the-evidence-on-tylenol-and-autism. Accessed 23 March 2026.

Clarinetist Katia Waxman, oboist Daniel Gurevich and pianist Ya-Ju Chuang played the final movement of the Trio for Oboe, Clarinet and Piano by Bill Douglas and spoke with IPR's Amanda Sewell. These three Interlochen faculty musicians will perform with guest flutist Alisa Smith in two recitals of woodwind chamber music with piano. The program features works by Eugène Bozza, Joseph Horovitz, Claude Debussy and Bill Douglas will be held on Saturday, February 28 at 7:30 p.m. at the Alluvion, part of the Interlochen in Town series. The musicians will also give an informal preview of the recital in the Music Center at Interlochen Center for the Arts on Thursday, February 26 at 7:30 p.m.

"The House hasn't reorganized committee jurisdictions since the early 70s—before the internet existed." — Maya KornbergAmerica is stuck stuck stuck stuck. Almost exactly a year ago, I interviewed the Atlantic's Yoni Applebaum about Stuck, his influential critique of the housing crisis. Now we have another Stuck—this one by Maya Kornberg, a senior fellow at the Brennan Center for Justice. Only her subtitle is about Congress, not housing: How Money, Media, and Violence Prevent Change in Congress.This is, Kornberg argues, one of the toughest times in modern American history to sit in Congress. Members are forced to spend most of their time making fundraising calls. They face record-high threats against themselves and their families. And the media incentivizes spectacle over policymaking—what she describes as "Kings and Prophets"—where members have the power of the megaphone but not the power to drive legislation.One fact captures Congressional stuckness: The House hasn't reorganized its committee jurisdictions since the early 1970s—before the internet existed. Half the Senate, then, questioned Mark Zuckerberg because no single committee is responsible for tech. Not even mad libertarians like Elon Musk could make that one up.Kornberg recently ran for New York City Council in Park Slope and, as a friend of Israel, discovered firsthand how media latches onto the most salacious angle. That said, she's not giving up on Congress. Kornberg is hopeful that a fresh wave of reformers, like the Watergate babies of '74 or the class of 2018, can unstick it. But she is, nonetheless, clear-eyed about what we're facing: a four-alarm fire for our democracy. Five Takeaways●      This Is the Hardest Moment in Modern History to Be in Congress: Members face astronomical campaign costs, record-high threats and violence against themselves and their families, and a leadership-driven system that has stripped rank-and-file members of real power to drive legislation.●      Money, Media, and Violence Keep Congress Stuck: Members spend every mealtime making fundraising calls. They pay "dues" to the party just to get on good committees. Media incentivizes spectacle over policymaking. And threats against members have risen year after year.●      Congress Hasn't Reorganized Since Before the Internet: The House hasn't reorganized committee jurisdictions since the early 1970s. Half the Senate questions Mark Zuckerberg because no single committee is responsible for tech. When everyone's responsible, no one is.●      More Chairmen Named Mike Than Women Committee Leaders: The pay-to-play system in Congress disadvantages women, communities of color, working-class Americans, and young Americans—anyone who faces greater barriers to fundraising faces greater barriers to power.●      Waves of Reformers Can Unstick Congress: The Watergate babies of '74, the Republican Revolution of '94, the class of 2018—frustrated reformers have reshaped Congress before. The midterms could bring another wave, if the public frustration is deep enough. About the GuestMaya Kornberg is a senior fellow at the Brennan Center for Justice. She holds a PhD from Oxford and is the author of Inside Congressional Committees. She recently ran for New York City Council in Brooklyn's Park Slope.ReferencesBooks mentioned:●      Stuck: How Money, Media, and Violence Prevent Change in Congress by Maya Kornberg — her new book on why Congress is stuck and how to unstick it.●      Stuck: How the Privileged and the Propertied Broke the Engine of American Opportunity by Yoni Applebaum — on the housing crisis, interviewed on this show a year ago.●      Why Nothing Works by Marc Dunkelman — on who killed progress and how to bring it back.People mentioned:●      Henry Waxman served four decades in Congress and passed landmark health and environmental legislation even under Reagan.●      Lauren Underwood came to Congress in 2018 and co-founded the Black Maternal Health Caucus after losing a friend who died after childbirth.●      Hélène Landemore is a Yale political theorist who advocates for citizen assemblies as an alternative to representative democracy.About Keen On AmericaNobody asks more awkward questions than the Anglo-American writer and filmmaker Andrew Keen. In Keen On America, Andrew brings his pointed Transatlantic wit to making sense of the United States—hosting daily interviews about the history and future of this now venerable Republic. With nearly 2,800 episodes since the show launched on TechCrunch in 2010, Keen On America is the most prolific intellectual interview show in the history of podcasting.WebsiteSubstackYouTubeApple PodcastsSpotify Chapters:(00:00) - Introduction: America is stuck (02:04) - Why everyone woke up to this problem at once (03:49) - Why study Congress? Is it boring? (06:33) - Money, media, and violence (07:11) - Congressional chameleons: Waxman, Underwood, Andy Kim (10:24) - Is this bipartisan? (12:37) - The crummiest job in Washington (15:53) - Money: 'I spend every mealtime making fundraising calls' (17:29) - Should Congress get a pay raise? (19:53) - Media and the Gaza third rail (23:14) - Kings and Prophets: Spectacle over policy (25:32) - Can Congress stand up to Trump? (27:43) - Congress is woefully unprepared to regulate tech (31:54) - Gerontocracy: More Mikes than women (37:34) - Can citiz...

Residency is one of the most profound life-changing seasons in a physician's journey—a time of rapid growth, deep uncertainty, and one of the biggest decisions of all: what comes next. In this unique collaborative episode, host Dr. Dael Waxman is joined by Charles Lowry, Director of Graduate Medical Education Relations at PracticeLink and host of the Surviving and Thriving in Residency podcast. Rather than a traditional interview, Dr. Waxman and Charlie engage in a shared conversation about the critical inflection points they've witnessed in medical students and residents. They explore the hidden struggles beneath the confident exterior—the loneliness, the imposter syndrome, the career uncertainty—and the powerful role that connection, validation, and intentional support can play. Together, they uncover how coaching and career resources can help residents move from survival mode to intentional choice, and why finding your "people" is essential for a sustainable, fulfilling career in medicine. Key Topics Discussed: Charlie's journey from statewide campus director for medical students to his current role supporting residents nationwide. The vulnerability and openness residents show when given a safe, non-evaluative space to share their struggles. The hidden stressors of residency: loneliness, lack of family support, and the challenge of being an international medical graduate. How PracticeLink serves as a free, comprehensive career resource for residents, from CV reviews to scholarships. The role of coaching in addressing imposter syndrome, leadership challenges, and the transition from training to practice. Why career uncertainty is a major driver of stress and well-being issues. Practical advice for residents: take advantage of free resources, find your community, and remember that residency is just one chapter. What gives both Dr. Waxman and Charlie hope about the next generation of physicians. Guest Information: Mr. Charles Lowry, Director of Graduate Medical Education Relations, PracticeLink. Email: charles.lowry@practicelink.com Website: practicelink.com Podcast: Surviving and Thriving in Residency PracticeLink offers free CV reviews, scholarships, webinars, and a robust job board for physicians at all stages. Relevant Links: MD Coaches: mymdcoaches.com Sponsor: PracticeLink – practicelink.com Sponsor: Navigate Student Loans – flipthescript.loan/md-coaches Sponsor: Physician Outlook – physicianoutlook.com MD Coaches Community on Facebook   -+=-+=-+=-+= Join the Conversation! We want to hear from you! Do you have additional thoughts about today's topic? Do you have your own Prescription for Success? Record a message on Speakpipe   Unlock Bonus content and get the shows early on our Patreon Follow us or Subscribe: Apple Podcasts | Google Podcasts | Stitcher | Amazon  | Spotify --- There's more at https://mymdcoaches.com/podcast Music by Ryan Jones. Find Ryan on Instagram at _ryjones_, Contact Ryan at ryjonesofficial@gmail.com Production assistance by Clawson Solutions Group, find them on the web at csolgroup.com

Michael and Tory Waxman — the founders of Sundays for Dogs, the Cleveland-based company designed to make dog parents' lives easy.What began with their own dog, Mabel, and a simple but powerful question — why does feeding dogs well have to be so difficult? — has grown into one of the most exciting consumer companies to emerge from Ohio. Led by loving dog parents Dr. Tory Waxman, a veterinarian, and Michael Waxman, a serial entrepreneur, Sundays pioneered human-grade, air-dried, zero-synthetics dog food designed to be healthier than kibble and easier than refrigerated alternatives.Since our last recorded conversation in 2023 (Lay of The Land Episode #123), Sundays has scaled dramatically. Having raised more than $55 million in capital and built out a Cleveland-based R&D Test Kitchen — where our conversation today took place — Sundays has grown from a direct-to-consumer upstart into a nationally recognized brand preparing for omni-channel distribution, creating a product that dogs love while positioning themselves at the forefront of the booming pet food market and the emerging ambient fresh movement.In our conversation, Michael and Tory share how they've navigated multiple chapters of scaling — including customer acquisition and brand evolution, balancing supply and demand, investing deeply in product innovation, and building a senior leadership team — while staying grounded in the mission that inspired Sundays from the start: making it easier to be an awesome dog parent. They also discuss what excites them most about the future and what comes next for Sundays as the company continues to grow.00:00:00 - "The World's Best Dog Food is Made in Cleveland"00:00:25 - Introduction: Sundays for Dogs00:05:20 - Building an In-House R&D Test Kitchen in Cleveland00:10:06 - Most Dogs Still Eat Kibble (And Why That's Changing)00:15:09 - Marketing Evolution: How Does Sundays for Dogs Stand Out?00:20:18 - New Recipe Launch Preview (From the Test Kitchen!)00:21:33 - Ohio: The Surprising Dog Food Capital of America00:25:36 - Supply Chain Stories & Lessons Learned00:30:39 - When Demand Outpaces Supply: A Good Problem?00:32:59 - Beyond DTC: Omnichannel Distribution Strategy00:38:21 - How AI Will Transform How People Buy Dog Food00:41:34 - Dogs as Family: Where Is Society Headed?00:46:44 - Building Company Culture at Sundays00:52:13 - The Vision: Making Sundays a Household Name00:55:18 - Where to Find Sundays for Dogs-----LINKS:https://sundaysfordogs.com/https://www.linkedin.com/in/michaelewaxmanhttps://www.linkedin.com/in/tory-waxman-87781b176/https://www.layoftheland.fm/123-tory-michael-waxman-sundays/-----SPONSOR:Roundstone InsuranceRoundstone Insurance is proud to sponsor Lay of The Land. Founder and CEO, Michael Schroeder, has committed full-year support for the podcast, recognizing its alignment with the company's passion for entrepreneurship, innovation, and community leadership.Headquartered in Rocky River, Ohio, Roundstone was founded in 2005 with a vision to deliver better healthcare outcomes at a more affordable cost. To bring that vision to life, the company pioneered the group medical captive model — a self-funded health insurance solution that provides small and mid-sized businesses with greater control and significant savings.Over the past two decades, Roundstone has grown rapidly, creating nearly 200 jobs in Northeast Ohio. The company works closely with employers and benefits advisors to navigate the complexities of commercial health insurance and build custom plans that prioritize employee well-being over shareholder returns. By focusing on aligned incentives and better health outcomes, Roundstone is helping businesses save thousands in Per Employee Per Year healthcare costs.Roundstone Insurance — Built for entrepreneurs. Backed by innovation. Committed to Cleveland.-----Stay up to date by signing up for Lay of The Land's weekly newsletter — sign up here.Connect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Lay of The Land on X @podlayofthelandhttps://www.jeffreys.page/

Editor in Chief and founder of "The Wrap," Sharon Waxman and yours truly weigh in on the Seismic Shiftiness rocking LaLa Land.     https://bit.ly/3Yfs6ea

Recorded live at the Museum of Contemporary Art Chicago / CAB Tailgate In this live MCA tailgate episode, the Bad at Sports crew — Duncan MacKenzie, Ryan Peter Miller, Brian Andrews, and Jesse Malmed — sit down with Chicago Tribune and Hyperallergic critic Lori Waxman to dig into the past, present, and uncertain future of art criticism.   Lori Waxman speaks candidly about being one of the last remaining "paper critics" in the Midwest, the strange privilege and responsibility of writing for a general audience, and the realities of practicing criticism in a media ecosystem that has largely abandoned it. The conversation moves between the lightly chaotic and the deeply reflective: the team discusses accountability, gatekeeping, democratization, descriptive vs. evaluative criticism, and the uneasy role of critics in shaping a city's cultural memory. A major portion of the episode is devoted to Waxman's long-running performance project "The 60 WRD/Min Art Critic," which she describes as part-service, part-performance, part-publishing experiment — one that temporarily gives a community something most cities no longer have: a local critic writing about local work. From describing her process of writing in public (fully clothed), to fielding questions about dead artists, visibility, taste, and how critics navigate their own spreadsheets, Waxman opens up her practice with humor and clarity. The episode also includes reflections on Chicago's art ecology, journalism's collapse, how artists use reviews, and what it means to keep going when the platforms keep disappearing. Names Dropped — With Links Lori Waxman

Good morning and thank you for watching Good Morning Aurora! Today's interview will be led by Yazmin Ortega-Garcia. She is a bilingual insurance agent and member of the GMA/BDA family! We are excited to welcome a new guest to our program this morning: Dr. Jonathan Waxman, Thoracic Surgeon at Rush Copley Medical Center. Our program is honored to share the great and meaningful work of RUSH on our program.November is Lung Cancer Awareness Month and Dr. Waxman and Hillary are her to talk about this disease, preventative measures and resources that are available to our community. After our show today more information will be shared on our channel to help anyone looking for assistance. Got questions? Send us an email to: goodmorningaurorail@gmail.comHave a great rest of the day! Good Morning Aurora will return with more news, weather and the very best of Aurora. Subscribe to the show on YouTube at this link: https://www.youtube.com/c/GoodMorningAuroraPodcastThe second largest city's first daily news podcast is here. Tune in 5 days a week, Monday thru Friday from 9:00 to 9:30 am. Make sure to like and subscribe to stay updated on all things Aurora.Threads: https://www.threads.net/@goodmorningaurorailInstagram: goodmorningaurorailSpotify: https://open.spotify.com/show/6dVweK5Zc4uPVQQ0Fp1vEP...Apple: https://podcasts.apple.com/.../good-morning.../id1513229463Anchor: https://anchor.fm/goodmorningauroraACTV (Aurora Community Television): https://www.aurora-il.org/309/Aurora-Community-TV#kanecountyil #bataviail #genevail #elginil #aurorail #auroraillinois #cityofaurorail #auroramedia #auroranews #morningnews #goodmorningaurora #wednesday #fyp #lungcancerawareness

Filmmaker Thomas J. Churchill (Amityville trilogy, Big Freaking Rat) joins ClassHorrorCast for a raw, inspiring talk on creative control, investor “cookie jars,” and staying fearless without a safety net.We trace his path from child actor to DIY director, the lessons of Devoured, why sound is his “first scare,” and how faith, family, and grief shaped the “Church-verse.”We dig into Amityville as a sandbox (vamps, werewolves, uprisings), why continuations beat reboots, and how Terrifier tapped old-school energy.Plus teases for Three Killer Pigs, Wax Man, and The Salem Chronicles. If you're an indie creator—or just love horror that swings for the fences—this one's for you.For more of my content - CLICK HEREFor more of Church - CLICK HEREBecome a supporter of this podcast: https://www.spreaker.com/podcast/class-horror-cast--4295531/support.

Choice Classic Radio presents to you Richard Diamond Private Detective, which aired from 1949 to 1953. Today we bring to you the episode titled "The Tom Waxman Bombing Case.” Please consider supporting our show by becoming a patron at http://choiceclassicradio.com We hope you enjoy the show!

There is much debate among academics and policy experts over the power the Constitution affords to the president and Congress to initiate military conflicts. But as Michael Ramsey and Matthew Waxman, law professors at the University of San Diego and Columbia, respectively, point out in a recent law review article, this focus misses the mark. In fact, the most salient constitutional war powers question—in our current era dominated by authorizations for the use of military force—is not whether the president has the unilateral authority to start large-scale conflicts. Rather, it is the scope of Congress's authority to delegate its war-initiation power to the president. This question is particularly timely as the Supreme Court appears growingly skeptical of significant delegations of congressional power to the executive branch.Matt Gluck, Research Fellow at Lawfare, spoke with Waxman and Ramsey about their article. They discussed the authors' findings about the history of war power delegations from the Founding era to the present, what these findings might mean if Congress takes a more assertive role in the war powers context, and why these constitutional questions matter if courts are likely to be hesitant to rule on war powers delegation questions.To receive ad-free podcasts, become a Lawfare Material Supporter at www.patreon.com/lawfare. You can also support Lawfare by making a one-time donation at https://givebutter.com/lawfare-institute.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.

"Everything about our waking being is affected by the food we eat. And it's not just where your food comes from, but the ingredients…with integrity. Who is putting their love and passion into a crop? Who is not taking the shortcuts? How are individual ingredients… affecting our overall mood, physicality, all those things. All this is coming to light now— this is not pseudoscience anymore." —Jennifer Waxman Every meal shapes more than our day—it shapes our health, our habits, and even our outlook. The world talks about superfoods and supplements, but the real power is digging into what grows close to home. By shifting perspective on our plate, we can change everything we thought we knew about wellness. Raised on homegrown food and practical kitchen wisdom, Seed2source co-founder, Jennifer Waxman, turned her roots into a mission to make agriculture accessible and meaningful. She's faced the challenges of new food technologies, bridged the gap between farms and hospitals, and built real-world solutions for everyday eaters. Today, she proves anyone can harness the benefits of smarter agriculture, even without expert know-how.  Expect surprising tips about local sourcing, honest talk about common food myths, behind-the-scenes glimpses at hospital nutrition programs, and smart strategies for bringing better produce (and practices) into your life—all served in this week's episode. Stream now!   Meet Jennifer: Jennifer Waxman, co-founder and managing partner at Seed2Source, began her career in agribusiness and natural wellness in 2000 after earning her MBA from Rollins College. She became a global leader in agricultural water conservation and hydroponics, gaining early insights into Controlled Environment Agriculture (CEA) before its U.S. emergence. In 2005, she founded a consulting firm focused on sustainable agriculture and wellness, managing supply chains and pioneering food-as-medicine models.  As Executive Director of The Villages Grown, she developed a community-centric, local food system business model. Jennifer is a respected mentor and advocate for the Local Food Movement, collaborating with major health and academic institutions. She educates on nutrient-dense growing and the health impacts of diet, emphasizing the link between agriculture and wellness. Her leadership spans board roles, keynote speaking, and editorial contributions across national and international agricultural organizations. Website Instagram  Email   Connect with NextGen Purpose: Website Facebook Instagram LinkedIn YouTube   Episode Highlights: 00:44 Meet Jennifer 04:11 Lessons Learned from Successes and Failures  07:34 Transitioning to Agriculture: Nurturing Plants and People 16:04 The Impact of Food as Medicine  21:59 Education and Empowerment in Agriculture  30:58 The Future of Agriculture and Its Broader Impact 36:16 Agriculture at the Roots of All Sectors  

What's driving opportunities in alternative assets, and how are investors adapting to an accelerating pace of change? Sixth Street Co-Founder, CEO, and Co-CIO Alan Waxman discusses his career and the importance of flexibility in finding alpha on the latest edition of Goldman Sachs Exchanges: Great Investors. This episode was recorded on September 3, 2025. The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products.  This material may contain forward-looking statements.  Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose.  Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs. A transcript is provided for convenience and may differ from the original video or audio content.  Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs.   © 2025 Goldman Sachs. All rights reserved. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Dynamic Duo is back! No, not Waxman and Professor Payne; it's Chris Franklin and Ryan Daly with a new episode of Batman Knightcast! This time the guys continue the stories from last issue starting with the origin of Clayface III in Detective Comics #478. Then, Bruce Wayne and Dick Grayson face the terrible threat of... Child Protective Services in Batman & Robin Year One #2. Have a question or comment? Looking for more great content? Leave comments on our website: https://fireandwaterpodcast.com/show/batman-knightcast-2/ Images from this episode: https://fireandwaterpodcast.com/podcast/batman-knightcast-39-image-gallery/ Subscribe to BATMAN KNIGHTCAST: Subscribe on Apple Podcasts: https://podcasts.apple.com/us/podcast/batman-knightcast/id1788229385 Don't use Apple Podcasts? Use this link for your podcast catcher: https://feeds.feedburner.com/knightcast Follow BATMAN KNIGHTCAST on social media: Facebook: https://www.facebook.com/BatmanKnightcast Bluesky: https://bsky.app/profile/batmanknightcast.bsky.social This podcast is a proud member of the FIRE AND WATER PODCAST NETWORK: Visit the Fire & Water WEBSITE: http://fireandwaterpodcast.com Like our Fire & Water Facebook page: https://www.facebook.com/FWPodcastNetwork Follow Fire & Water on Twitter/X: https://x.com/FWPodcasts Follow Fire & Water on Bluesky: https://bsky.app/profile/fwpodcasts.bsky.social Support The Fire & Water Podcast Network on Patreon: https://www.patreon.com/fwpodcasts Music: “The Batman Theme: Epic Version (feat. Mask of the Phantasm + Imperial March” arranged by Samuel Kim. Check it out on Youtube right here: https://youtu.be/m-AnLl9Vyb8?si=H5SsJPY_L8FMdtG5 Additional music: “I Melt with You" by Modern English Thanks for listening!

【主播的话】整整两年之前，2023年的十月份，以色列跟巴勒斯坦之间爆发了新一轮的严重冲突，并恶化为一场旷日持久的战争、以及一场接一场的人道惨剧。那天之后，世界似乎开始了一种持续至今的撕裂。在加沙，成千上万的人每天都在受难，饥饿、暴力、失踪、流离失所、残疾、死亡。与此同时，这场战争的回声，也在战场之外的地方不断回荡——在中东邻国、在美国、在欧洲，在大学校园里，在政治辩论中，在社交媒体上。过去两年里，围绕加沙的争论几乎无处不在：抗议、辞职、取消、抓捕、撤资。它不仅是外交政策的争议，更成了一场关于身份、道德与立场的内战。对许多年轻人来说，这不仅是关于中东的问题，而是关于“我们是谁”，以及“我们还能相信什么样的正义”。今天的节目分为两个部分。第一部分，主要谈中东。我们邀请了中东观察家刘怡，来梳理加沙战争两周年的重要节点，从巴以出发，探讨它对中东局势的影响。第二部分，重点在美国。我们邀请了常驻纽约的美国观察家思骋，来解读加沙战争对美国内政外交的影响。【本期主播】王磬：微博@王磬【本期嘉宾】刘怡：前《三联生活周刊》资深主笔，全球冲突报道者思骋：美国政治观察家，常驻纽约【本期剧透】03:32 加沙战局转向虚无，冲突轨迹受特朗普决策主导，军事行动与政治目标逐渐脱节09:18 加沙正在面临怎样的人道灾难？以色列系统性制造饥荒的现状11:22 战前加沙的畸形供给体系：以色列默许哈马斯控制国际援助流通，形成“物资可进、人员禁入”的共谋式封锁17:45 开战后，加沙生存体系崩溃，黑市物价暴涨50倍19:20 外援切断，美国仅派驻4个物资救援点，平民陷入平静的绝望24:39 犹太人定居点不断增加，西岸巴控区萎缩，武装定居者与隔离墙形成“蚕食式占领”新常态29:24 以色列社会的极端化转向，右翼基本盘稳固化，政治光谱整体右移34:01 巴勒斯坦群体的立场分化：海外巴勒斯坦裔激进口号与本土民众务实诉求42:35 阿拉伯世界的“道义卸责”：亚伯拉罕协议如何改变海湾国家对巴以问题的传统立场？48:10 哈马斯与伊朗构建的宗教抵抗同盟，如何替代传统阿拉伯民族主义？52:29 西方话语道德滑坡，两年间巴勒斯坦苦难从“被忽视”到“被犯罪化”57:40 2025年夏季为舆论分水岭，特朗普政府强硬压制舆论引发民意反弹01:02:05 “以色列替西方干脏活”：战后自由主义需要暴力维系01:06:56 在西方世界，为什么对反以色列政府的言论打压，比在以色列境内还要严厉？01:12:27 美国犹太社群的代际裂变，支持以色列如何从族群共识沦为矛盾源01:18:48 反犹主义如何被定义？又如何成为政治打压的工具？01:25:24 美国民主党出现政治代沟，年轻人在巴以议题和经济前景上面临双重挫败感【相关阅读】 Alex de Waal英国人类学家、公共政策学者与人权活动家，目前于美国马萨诸塞州塔夫茨大学法与外交学院（The Fletcher School）任研究教授。他自 1980 年代起在苏丹及非洲之角（Horn of Africa）地区开展“饥荒”研究，探讨饥荒的政治、社会与人权维度。研究立场强调：现代饥荒并非单纯由自然灾害或粮食短缺引起，而往往是政策失败、冲突、封锁与权力结构所致。其在饥荒领域的重要作品包括：《Mass Starvation: The History and Future of Famine》（2018）系统地回顾现代饥荒的历史：饥荒为何在 20 世纪下半叶大幅减少；为何在近年来又出现复苏；并指出饥荒多数为“人为”而非“自然”现象。《Famine Crimes: Politics and the Disaster Relief Industry in Africa》（1997）在本书中，de Waal 批判了传统救灾机构对饥荒背后政治与权力结构的掩盖，强调饥荒中的致命性常源于战争、封锁、治理失败，而非单纯粮食供应不足。 Masha Gessen 出生于俄罗斯莫斯科、后来获得美国公民身份的记者、作家和公共知识分子。写作涉猎广泛，涵盖俄罗斯现代史、威权主义、性别与 LGBTQ 议题、美国与俄罗斯关系、乌克兰冲突等。自 2017 年起担任《The New Yorker》的正式撰稿人。其代表作包括《The Future Is History: How Totalitarianism Reclaimed Russia》（2017年获美国国家图书奖）等。她以批判权威主义、剖析自由与专制之间的张力著称。 《Trouble in the Tribe: The American Jewish Conflict over Israel》作者：Dov Waxman出版信息：Princeton University Press，2016 年Dov Waxman 为 UCLA 以色列研究教授，研究方向包括以色列政治、美国—以色列关系与美国犹太社群。Waxman 通过大量访谈与民调数据，分析近年来美国犹太社群围绕以色列问题的深刻分歧：一方面年长与更传统的群体维持强烈支持，另一方面年轻与自由派群体越来越公开批评以色列政策。书中探讨了文化、人口学、组织与政治因素如何导致“以色列不再成为团结来源、而日益成为分裂来源”的局面，对美国犹太政治与以美关系的未来提出判断。 《最后的乌托邦：历史中的人权》The Last Utopia: Human Rights in History作者：Samuel Moyn出版信息：商务印书馆，2016 年Samuel Moyn 是美国耶鲁大学（Yale University）法律与历史双聘教授，专攻现代欧洲思想史、国际法与人权史。本书提出一个颇具挑战性的观点：当今“人权”作为普遍正义话语并非源远流长，而是在1960 年代末至 1970 年代初，在全球政治与意识形态乌托邦（社会主义、民族解放运动）瓦解之后，才真正成为国际社会关注的核心。作者通过回顾冷战背景下欧洲、拉丁美洲、美国等地的个案，指出人权运动如何在旧有政治理想失败的废墟上兴起，并探讨其作为“最后的乌托邦”之意味 —— 即人权为何成为替代以往政治理想的新信仰。【特别鸣谢】蓝书屋基金会（Blaues Haus Stiftung）【本期音乐】Bleu-KomikuScreen Saver-Kevin MacLeod【节目制作】方改则【Logo设计】刘刘（ins: imjanuary)【互动方式】小红书@不合时宜微博@不合时宜TheWeirdo商务合作可发邮件至 hibuheshiyi@126.com 或微博私信会员计划咨询可添加微信：hibuheshiyi3 或发送邮件至 hibuhehsiyi@gmail.com

Urban Institute senior fellow Elaine Waxman and Jeremiah Program president and CEO Chastity Lord know the power of single moms on the economic mobility of entire communities. “Great moms are dreaming in threes: they dream for themselves, they dream for their children, and they naturally dream for their community,” says Lord. The Jeremiah Program supports single mothers as they invest simultaneously in their own goals as well as their children's education. Waxman recently published “Policy Levers to Support Single-Mother Economic Mobility” with support from Share Our Strength. “I always think of food insecurity as the canary in the coal mine. It's often the first symptom of instability to emerge because that's a quick way that people can try to move resources around. It's also often one of the last ones to resolve,” she reports.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

durée : 01:01:52 - Les Nuits de France Culture - par : Albane Penaranda, Mathias Le Gargasson, Antoine Dhulster - Dans ce cinquième volet d'Euphonia – "Les Hollywoodiens", Noël Simsolo et le critique Jean Douchet s'intéressent à la collaboration entre Franz Waxman et Alfred Hitchcock. Quatre films seulement, qui influenceront profondément le réalisateur lors de sa collaboration ultérieure avec Bernard Herrmann. - réalisation : Massimo Bellini, Vincent Abouchar - invités : Jean Douchet Cinéaste, historien et critique de cinéma (1929-2019)

Matt Waxman, adjunct senior fellow for law and foreign policy and Liviu Librescu Professor of Law at Columbia University sits down with James M. Lindsay to discuss the legality of the Trump administration's military strikes against drug traffickers and the implications for U.S. foreign policy.   Mentioned on the Episode:   James Madison, “Federalist No. 51,” The Federalist Papers   For an episode transcript and show notes, visit The President's Inbox at: https://www.cfr.org/podcasts/tpi/legality-trumps-drug-boat-strikes-matthew-waxman

Sadly, and without much fanfare, we lost another dedicated film music fan and a very good friend, Tom Kiefner. November 2, 1947 – June 13, 2025. He was a gentle soul, a passionate baseball fan and a skilled photographer. I initially met Tom in the early 2000s when I joined a message board on scorereviews.com, which is now maintitles.net. There, I read Tom's enthusiastic postings about melodic, orchestral Golden Age scores, and classical music. He would wax poetic about Korngold, Rozsa, Waxman, Herrmann, Tiomkin, Newman and Hugo Friedhofer who peened his favourite score of all time, THE BEST YEARS OF OUR LIVES. He would often express his admiration for early television shows and the music composed for them including Lalo Schifrin's MISSION: IMPOSSIBLE and Morton Stevens' HAWAII-FIVE-O. I befriended Tom, and we talked about film music and his other interests, such as photography and baseball. He once told me that he casually chatted with Wayne Gretzky, whose son played for one of the teams Tom was photographing that day. The discussions would continue to include Hammer Horror films, Les Baxter, Charles Gerhardt, and Tom's dream of starting a website dedicated solely to Golden Age scores. I thought it was a great idea. He then offered me money to create the website for him. Even if I could… I don't have the skills to do so… I would never take Tom's money. I then suggested he contact Bregt De Lange, who designed the maintitles.net website. GoldenScores.com launched in 2006. After the site closed a few years later, Tom moved his film music essays and reviews to his new WordPress blog, Film and Classical Music: Neglected Art. There, Tom's writings, which began in 2006, are archived. His last review was on May 4, 2022. In 2010, Tom accepted an invitation to guest-host his own episode of Cinematic Sound Radio. I told him he could play whatever he wanted, as long as it was Golden Age-themed. These are the original show notes. FILM MUSIC MIX | GOLDEN AGE SCORES with guest host TOM KIEFNER from FILM MUSIC: THE NEGLECTED ART On this edition of FILM MUSIC MIX guest host Tom Kiefner from the film music blog, FILM MUSIC: THE NEGLECTED ART, will take us on a journey through the wonderful sounds of Hollywood's Golden Age. You will hear music by Bernard Herrmann from the film HANGOVER SQUARE featuring the Concert Macabre. You'll also hear a couple of selections from THE BEST YEARS OF OUR LIVES by Hugo Friedhofer (Tom's favorite score) and a spectacular suite from HORROR OF DRACULA by James Bernard. Afterwards, enjoy the Americana sounds of Aaron Copland with THE RED PONY and finish off with the tune that got Tom into film music; the up tempo theme from PETER GUNN by Henry Mancini. So, on today's very special episode, and in honour of one of the great champions of film music and my friend, we proudly rebroadcast Tom's show, which first premiered on September 3, 2010. Rest in peace, my friend! —— Special thanks to our Patreon supporters: Matt DeWater, David Ballantyne, Joe Wiles, Maxime, William Welch, Tim Burden, Alan Rogers, Dave Williams, Max Hamulyák, Jeffrey Graebner, Don Mase, Victor Field, Jochen Stolz, Emily Mason, Eric Skroch, Alexander Schiebel, Alphonse Brown, John Link, Andreas Wennmyr, Matt Berretta, Eldaly Morningstar, Jim Wilson, Glenn McDorman, Chris Malone, Steve Karpicz, Deniz Çağlar, Brent Osterberg, Jérôme Flick, Sarah Brouns, Aaron Collins, Randall Derchan, Angela Rabatin, Michael Poteet, Larry Reese, William Burke, Rudy Amaya, Stacy Livitsanis, Rick Laird, Carl Wonders, Nathan Blumenfeld, Lee Wileman, Daniel Herrin, Scott Bordelon, James Alexander, Brett French, Ian Clark, Ron, Andy Gray, Joel Nichols, Steve Daniel, Corey O'Brien, John Leggett, Mim Williams, Grace Hamilton, Rob Kemp. —— Cinematic Sound Radio is fully licensed to play music by SOCAN. Support us on Patreon https://www.patreon.com/cinematicsoundradio Check out our NEW Cinematic Sound Radio TeePublic Store! https://www.teepublic.com/stores/cinematic-sound-radio Cinematic Sound Radio Web: http://www.cinematicsound.net Twitter: http://www.twitter.com/cinsoundradio Facebook: http://www.facebook.com/cinematicsound Cinematic Sound Radio Fanfare and Theme by David Coscina https://soundcloud.com/user-970634922 Bumper voice artist: Tim Burden http://www.timburden.com

In the Public Interest is excited to continue In That Case, its third annual miniseries examining notable decisions recently issued by the United States Supreme Court. In this episode, host Felicia Ellsworth is joined by Partner and Chair of WilmerHale's Appellate and Supreme Court Litigation Practice Seth Waxman and Counsel Zaki Anwar to discuss Glossip v. Oklahoma. The case concerns Richard Glossip, who has been on death row since 1998 on a first-degree murder charge. The team arguing on his behalf in front of Court, which included Waxman and Anwar, successfully argued that Glossip's sentence should be reversed and the state of Oklahoma should be allowed to retry his case.Waxman and Anwar walk through each step of the case, outlining the complex procedural history that has taken place over the course of nearly thirty years. They emphasize the significance of the case for due process and other capital cases in the future, and what it reflects about the current Court's ideologies when it comes to serious criminal convictions.

Designing the experience is pretty much all we focus on. From the colors, textures, sounds, layouts - to the drinks themselves, people's experience is something that is born from design. If we want it to be a good one, we need to put in specific effort across many different areas. One of the areas today' encore episode guest focuses on is the building and space itself where guest drink their coffee and form opiniions that build our business or erode trust.  Today we are re-airing a wonderful episode about designing the guest experince with Dr. Lisa Waxman PHD.  Dr. Lisa Waxman, Ph.D. is an award winning professor and chair of the Interior Architecture + Design department at Florida State University. Her research includes topics related to the design of spaces that foster community, sustainable design, and design for special populations. She also serves on the board of directors for the Council for Interior Design Accreditation (CIDA). Dr. Waxman has many scholarly and creative works to her name but we will be focused on one particular study "The Coffee Shop: Social and Physical factors Influencing Place Attachment" She also has written the book, Designing Coffee Shops and Cafes for Community Please enjoy this episode and make it your goal to take action on utilizing these insights in your cafe!  Listen to these related episodes! 367 : Designing Your Coffee Shop for Community w/ Dr. Lisa Waxman Culture and Connection w/ Armen Alajain of Arto Brick 240 : What to do before your Build your Bar 343 : Founder Friday! “Curated Edition” | Hospitality + Meeting People Where They Are   SIGN UP FOR THE FALL KEY HOLDER COACHING GROUPS!  2025 Coaching Groups    KEYS TO THE SHOP OFFERS 1:1 CONSULTING AND COACHING! If you are a cafe owner and want to work one on one with me to bring your shop to its next level and help bring you joy and freedom in the process then email  chris@keystothshop.com of book a free call now:  https://calendly.com/chrisdeferio/30min      Want a beautiful coffee shop? All your hard surface, stone, Tile and brick needs!  www.arto.com Visit @artobrick The world loves plant based beverages and baristas love the Barista Series!  www.pacificfoodservice.com  

For over 40 years, Helena Bonham Carter has delighted us with roles including Lucy Honeychurch in Room with a View, Princess Margaret in The Crown and Harry Potter's much-loved villain, Bellatrix Lestrange. She joined Nuala McGovern to discuss her latest role in new film, Four Letters of Love, based on the bestselling book of the same name. Eight babies have been born in the UK using genetic material from three people to prevent devastating and often fatal conditions. The method, pioneered by UK scientists, combines the egg and sperm from a mum and dad with a second egg from a donor woman. The technique has been legal in the UK for a decade but this is the first proof it is leading to children born free of incurable mitochondrial disease, which is normally passed from mother to child. Anita Rani was joined by Kat Kitto who has two daughters, one of whom has mitochondrial disease, and Louise Hyslop, consultant embryologist at the Newcastle Fertility Centre to discuss.A new report by London's Victims' Commissioner, Claire Waxman, says that victims are being forced to quit the criminal justice system in huge numbers amid record court delays and traumatic process. She joined Nuala to explain why they are saying 'there is a near total failure in seeing offenders brought to justice', especially when it comes to female victims of violence. In the second part of our series about women and gaming, we find out more about the impact gaming can have on women's lives. Nuala heads to the Virgin Media Gamepad at the O2 to meet some of the women from the Black Girl Gamers community, who have over 10,000 members around the world. The bestselling author Louise Candlish joined Anita to talk about her latest novel - A Neighbour's Guide to Murder - which explores the practice of sex for rent and a trial by social media. The American jazz singer Samara Joy has five Grammy awards to her name and is quickly gaining superstar status in the jazz world. She is making her debut at the BBC Proms tonight, where she will be backed by the BBC Concert Orchestra, in a special tribute to the Great American Songbook. The Prom will be also be live on Radio 3, on BBC Four and iPlayer.Presenter: Anita Rani Producer: Annette Wells Editor: Deiniol Buxton

A new report by London's Victims' Commissioner, Claire Waxman, says that victims are being forced to quit the criminal justice system in huge numbers amid record court delays and traumatic process. She joins Nuala McGovern in the Woman's Hour studio to explain why they are saying 'there is a near total failure in seeing offenders brought to justice'.What are your attitudes towards money and specifically saving it, rather than spending it? Are you confidently playing the markets or are you still tucking it away under the mattress for a rainy day? Traditionally women have been thought of as risk-averse when it comes to putting their money into stocks and shares. Is that about to change? And is there such a thing as the 'gender investment gap'? To discuss women's attitudes towards investing we hear from Dr. Sara Reis, deputy director and head of policy and research at the Women's Budget Group think tank. Actor Miranda Raison has played numerous stage, screen and TV roles including the iconic Jean Seberg and Anne Boleyn but now takes on the role of the legendary Victorian actress Ellen Terry in a new play by David Hare - Grace Pervades at the Theatre Royal Bath. It tells the story of her relationship with Henry Irving, played by Ralph Fiennes, the greatest stars of the Victorian stage. Miranda discusses her latest role.News of fresh guidance from the government for relationships, sex and health education in schools. Responding, to what it says, is an increase in the harmful and misogynistic content, children are exposed to online. According to recent research, when asked about just the past week, over a third of pupils aged 11-19 had heard comments that made them worry about girls' safety, and more than half witnessed comments they would describe as misogynistic. The BBC's Education Editor Branwen Jeffreys updates us.Despite making up almost half of gaming audiences, just 30% of games industry workers are women. In the next part of our series on women and gaming, we're finding out why this is and what can be done to get more women into the industry. Charu Desodt, who was the first female engineer at Sony's London studio in 1999, and Tara Mustapha, founder of Code Coven, discuss. Presenter: Nuala McGovern Producer: Kirsty Starkey

My guest today is Alan Waxman. Alan is the co-founder and CEO of Sixth Street, one of the most unique investment firms with a "go anywhere, do anything" mandate across asset classes, geographies, and time horizons, and over $110 billion in AUM. He describes his journey from CIO of Goldman Sachs' Special Situations Group and the frameworks he brought with him to lay the foundation for Sixth Street. Alan details their famous investments like Spotify and Airbnb during challenging periods, their innovative sports partnerships with Real Madrid and FC Barcelona, and their $30 billion "TAO" vehicle that allows them to write billion-dollar checks while keeping individual fund sizes matched to opportunities. We discuss hiring people without egos, enabling a truly multi-strategy approach, and Sixth Street's "face the tiger" philosophy. Please enjoy this great conversation with Alan Waxman.  For the full show notes, transcript, and links to mentioned content, check out the episode page⁠⁠⁠⁠ ⁠⁠⁠⁠⁠here⁠.⁠⁠⁠⁠⁠⁠⁠⁠ ----- This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ramp⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ramp's mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ramp.com/invest⁠⁠⁠⁠⁠⁠⁠⁠⁠ to sign up for free and get a $250 welcome bonus. – This episode is brought to you by⁠⁠⁠⁠⁠ AlphaSense⁠⁠⁠⁠⁠. AlphaSense has completely transformed the research process with cutting-edge AI technology and a vast collection of top-tier, reliable business content. Invest Like the Best listeners can get a free trial now at⁠⁠⁠⁠⁠ Alpha-Sense.com/Invest⁠⁠⁠⁠⁠ and experience firsthand how AlphaSense and Tegus help you make smarter decisions faster. – This episode is brought to you by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Ridgeline⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Head to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ridgelineapps.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to learn more about the platform. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠). Show Notes: (00:00:00) Welcome to Invest Like the Best (00:04:57) Introducing Alan Waxman and Sixth Street (00:05:58) The Formative Goldman Sachs Years (00:10:21) Unitizing Risk and Return (00:14:23) Facing the Tiger: Sixth Street's Culture and Values (00:34:51) Spotify and Airbnb: Case Studies in Investment (00:39:20) Ambitious Investment Strategies (00:40:40) Strategic Partnerships in Sports (00:41:23) Navigating COVID with Airbnb (00:43:36) Risk and Return Analysis (00:46:56) Investing in Sports and Live Entertainment (00:52:23) Developing Investment Themes (00:55:29) Balancing Leadership and Investment (00:57:30) The Importance of Culture (01:10:33) Future Self and Long-Term Vision (01:15:09) The Kindest Thing Anyone Has Ever Done For Alan

Health plans continue to face operational delays due to fragmented systems and an over-reliance on manual reporting cycles. While data analysts work across multiple platforms to produce static reports, the insights often arrive too late to support real-time decisions. This episode explores why traditional models are no longer sustainable and how self-service dashboards, powered by a connected data ecosystem, are transforming operational agility. Listeners will hear how prebuilt metrics provide immediate visibility across functions such as claims, call center performance, and ID card fulfillment, enabling teams to respond faster, stay compliant, and enhance member outcomes. The discussion also covers adoption strategies, ROI considerations, and the organizational shift toward on-demand, decision-ready data.Listen now to discover how leading health plans are moving from reactive operations to real-time insight, without relying on analysts.About Our Guest: Michael Waxman is a health plan operations leader with over 20 years of experience as a health payer consultant at PwC and EY. He recently served as the Director of Business Operations for the post-implementation operations of HealthProof's technology ecosystem for a Medicare Advantage client. Using HealthProof's self-service dashboard, he ensured operational alignment for the health plan's provider data, claims, credentialing, cross-functional alignment for call center, disputes, utilization management, and more. Today, Waxman is a member of the Advisory Services team at HealthProof.

Howie and Harlan are joined by Stephen Waxman, a leading neurology researcher, to discuss the promise of new methods developed by his lab to treat the ravages of pain. Harlan talks about the importance of ratings for Medicare Advantage plans; Howie assesses two sobering new reports on the solvency of Medicare. Links: Harlan's Section  Slides from Humana's Investor Day  "Humana's cautious defense of Medicare Advantage" "What Are the Medicare Star Ratings?"  "Early analysis: How health plans fared in the 2025 Medicare Advantage star ratings" Interview with Dr. Waxman  "F.D.A. Approves Drug to Treat Pain Without Opioid Effects" "A brief historical perspective: Hodgkin and Huxley" "A quantitative description of membrane current and its application to conduction and excitation in nerve" Nobel Prize: “Speed read: Signal to charge" "Sodium channels and pain" "Targeting a Peripheral Sodium Channel to Treat Pain" Girl with the Dragon Tattoo: "Ronald Niedermann"  "Peripheral Sodium Channel Blocker Could Revolutionize Treatment for Nerve Pain" "Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain"  "Pharmacotherapy for Pain in a Family With Inherited Erythromelalgia Guided by Genomic Analysis and Functional Profiling"  "Neuropathic Pain" "A historical perspective on the discovery of statins"  "Erythromelalgia" "The Two Sides of NaV1.7: Painful and Painless Channelopathies"  "Dr. Stephen Waxman awarded Sharpey-Schafer Prize for pain research" Nobel Prize: "Robert Edwards" "Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons"  "Scientists Identify Method to Study Resilience to Pain"  "Chasing the genes behind pain"  "Stephen Waxman: pioneer in axons, their disorders, and pain" "I Feel Like I'm Burning Alive. It's Hard for People to Believe Me"  "‘How badly does it hurt?' Challenges of measuring pain in clinical trials" Howie's Section "2025 Medicare Trustees Report"  "Analysis of the 2025 Medicare Trustees' Report"  "Medicare gets a big (unofficial) surprise: a 17-year extension on when it'll run dry"  "Evan Sussman: Expanding Access to Fertility Drugs"  "Trump gives major lift to 2026 Medicare Advantage payments"  "June 2025 Report to the Congress: Medicare and the Health Care Delivery System"  "Medicare Advantage's supplemental benefits will cost taxpayers $86 billion this year, with little transparency"  "How UnitedHealth turned a questionable artery-screening program into a gold mine"  "From boom to bitcoin: A device maker's surprising pivot amid a Medicare crackdown"   Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

As Co-Founding Partner and CEO of Sixth Street, Alan has guided the firm from its founding to a leading global investment firm — an achievement that followed his early success as one of Goldman Sachs' youngest-ever partners. He offers an inside look at Sixth Street's investor-first approach and shares his perspectives on today's investment landscape.

Evelyn chats with Abbi Waxman about ONE DEATH AT A TIME, in which a cranky former actress teams up with her Gen Z sobriety sponsor to solve the murder that threatens to send her back to prison.

In this conversation, Matt Waxman shares his journey from a marketing major to a successful figure in the insurance industry, discussing his experiences in hospitality, insurance claims, and marketing. He emphasizes the importance of understanding the property market, particularly in challenging areas like Florida and Texas, and offers valuable advice for agents navigating these tough times. The discussion also touches on the evolution of his company, Alchemy Insurance Solutions, and the opportunities within the builders risk space. In this conversation, Matt Waxman and Heath Shearon delve into the complexities of Builders Risk insurance and the emerging cannabis insurance market. They discuss the importance of building strong relationships with underwriters, understanding client needs, and the necessity of educating producers on these specialized insurance products. The dialogue emphasizes the need for agents to develop pipelines for Builders Risk and the lucrative opportunities within the cannabis sector, highlighting the evolving nature of these industries and the role of Alchemy Insurance Solutions in providing comprehensive coverage solutions.takeawaysMatt Waxman has a diverse background in marketing, hospitality, and insurance.He transitioned from a marketing major to a career in insurance after exploring various fields.Waxman emphasizes the importance of building relationships in the builders risk market.The property market presents challenges, but also opportunities for agents willing to adapt.Alchemy Insurance Solutions focuses on solving pain points in the insurance market.Understanding the needs of clients is crucial for success in insurance.Waxman encourages agents to prepare thoroughly when submitting risks to underwriters.Flexibility in underwriting is essential in today's property market.The builders risk space can lead to long-term relationships with clients.Agents should not give up on finding coverage solutions for their clients. The likelihood of declination increases without proper partnerships.Understanding Builders Risk is crucial for effective insurance solutions.Building relationships with underwriters is essential for agents.Providing detailed information to underwriters enhances approval chances.Agents must sell both to clients and carriers effectively.The cannabis insurance market presents significant opportunities.Education and webinars are vital for agents to succeed in niche markets.Direct access to underwriters fosters better communication and solutions.Agents should be transparent about their knowledge in niche markets.The insurance landscape is evolving, requiring adaptability from agents.05:52Matt Waxman's Journey to Insurance10:32Cornerstone to Alchemy: Evolution of a Company18:00Navigating the Property Market Challenges20:06Advice for Agents in a Tough Market21:54Navigating the Builders Risk Landscape28:10Understanding the Role of Underwriters32:32Building a Pipeline for Builders Risk35:53Exploring the Cannabis Insurance Market40:07The Science Behind Cannabis Insurance45:53Alchemy Insurance Solutions: A Comprehensive OverviewMy amazing Sponsors;Smart ChoiceCanopy ConnectOlde School Marketing 

We're joined by Abbi Waxman for a fun chat all about her new book One Death at a Time, unnecessary birthing scenes, crying at Instagram reels, and why she loves a good Irish goodbye. Plus – Dave is shocked at his fellow teachers' attitudes concerning AI, Laura goes under the knife, and Andrew has concerns … Continue reading Ep. 288 Having A Good Cry With Abbi Waxman

Originally released in January 2023, CW: SA, violenceOn June 23 1993, after enduring years of physical and emotional abuse, Lorena Bobbitt infamously cut off the p*nis of her sleeping husband, John Wayne Bobbit. The case instantly becomes content for the 24 news cycle and a joke for late night comedians but the backstory is much more sinister. In this episode, we will discuss how Lorena was a victim of domestic abuse during a time when there were no laws and few systems in place to protect or help women stuck in dangerous relationships.We will also examine the trials of John and Lorena, gender bias in the media and the court room, domestic violence and the difficulty of leaving abusive situations. Lastly, we'll go over why this story is still important to talk about thirty years later and ask whether there are more options now than there were then. Sources: Bell, Rachael. "Crimes Below the Belt: Penile Removal and Castration (Chapter 2)". Crime Library. October 5, 2007. Chen, Joyce "Fine, We Can (Briefly) Talk About John Wayne Bobbitt's… Career" Refinery29. February 16, 2019.Effron, Lauren; Dooley, Sean. "John Bobbitt speaks out 25 years after".ABC News. Mead, Rebecca. The Lorena Bobbitt Story Offers New Lessons On Male Vulnerability (February 15, 2019).The New Yorker. Pershing, Linda (2011). ""His Wife Seized His Prize and Cut It to Size": Folk and Popular Commentary on Lorena Bobbitt". Smolowe, Jill; Peterzell, Jay (November 22, 1993). "TIME Magazine-Swift Sword of Justice". Waxman, Olivia. Lorena Bobbitt on Domestic and What She Wants You To Know About Her Case 25 Years Later (June 22, 2018).Time. 20/20 “The Bobbits” ABC News Lorena, Amazon Documentary Series Virginia Vs. Lorena Bobbitt, Court TV.Become a supporter of this podcast: https://www.spreaker.com/podcast/broads-next-door--5803223/support.

When Julia Mann, a bad-tempered ex-actress and professional thorn in the side of authority, runs into Natasha Mason at an AA meeting, it's anything but a meet-cute. Julia just found a dead body in her swimming pool, and the cops say she did it (she already went to jail for murder once, so now they think she's making a habit of it). Mason is eager to clear Julia's name and help keep her sober, but all Julia wants is for Mason to leave her alone.As their investigation ranges from the Hollywood Hills to the world of burlesque to the country clubs of Palm Springs, this unconventional team realizes their shared love of sarcasm and poor life choices are proving to be a powerful combination. Will secrets from their past trip them up, or will their team of showgirls, cat burglars, and Hollywood agents help them stay one step ahead? Are dead piranhas, false noses, and a giant martini glass important clues or simply your typical day in Los Angeles? And will they manage to solve the crime before they kill each other, or worse, fall off the wagon? Trying to keep it simple and take it easy is one thing—trying to find a murderer before they kill again is a whole other program.Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://brandyschillace.com/peculiar/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://eepurl.com/ixJJ2Y⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/PeculiarBookClub/membership⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@PeculiarBookClub/streams⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bluesky: ⁠⁠@peculiarbookclub.bsky.social⁠⁠Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@peculiarBC⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠facebook.com/groups/peculiarbooksclub⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@thepeculiarbookclub⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Listen in as I chat with Heather Waxman about 3 misconceptions about healing! As always, Heather brings so much knowledge, compassion, and good perspective to this episode!3 misconceptions we talk about:You heal a pattern once and it's doneTime heals all woundsHealing means never feeling pain againHeather Waxman is a therapist, breathwork facilitator, and author of Your True Nature Oracle. She earned her Master's Degree in Marriage and Family Therapy from Fairfield University. Through an artful and dynamic blend of therapeutic support, spiritual counsel, and somatic practices, Heather supports individuals, couples, and families navigating major life transitions, seasons of change, and cycles of death-and-rebirth to come home to their true nature. She works with people 1:1 both in-person and virtually through her private coaching practice, in groups through her community breathwork ceremonies, and works part-time as a therapist at Causeway Collaborative in Westport, Connecticut.Heather's website: https://www.heatherwaxman.com/OTD website: https://www.openingthedoorpodcast.com/

Every day, 10,000 people in the United States turn 65—a statistic that underscores one of the most significant demographic shifts in history. But the story of longevity is not just about aging, it's about learning new ways of living, working, and thriving across all life stages. From doctor's offices to government policies to popular culture, far too many of us erroneously associate aging with decline. How can we redefine aging to prioritize quality of life? Research shows that individuals have far more control over how they age than anyone imagined. We are shifting from a paradigm of decline to one that more accurately embraces the full spectrum of human flourishing while acknowledging biological realities. In this timely discussion, Barbara Waxman, renowned gerontologist and creator of The Longevity Roadmap, joins award-winning broadcaster Michael Krasny to explore the fascinating journey that brought us to this critical juncture in human history. They'll examine our current challenges, unveil cutting-edge insights about longevity, and share practical strategies for building a more resilient, fulfilling life at any age. Join us to discover actionable tools to take control of your aging journey and thrive in an era of unprecedented possibilities as we unpack the history, challenges, and opportunities of this remarkable demographic gift unfolding before us. About the Speakers Barbara Waxman is a gerontologist, coach, and longevity advocate who has spent four decades transforming people's understanding of aging. As creator of The Longevity Roadmap, she translates cutting-edge research into practical frameworks. A graduate of Colgate University with Master's degrees in gerontology and public administration from USC, Waxman is an advisor to the Stanford Center on Longevity and Stanford Lifestyle Medicine. Her insights have been featured on "CBS This Morning," in The Wall Street Journal, and across national media. She is a member of the American College of Lifestyle Medicine and author of The Middlescence Manifesto. Michael Krasny is a literary critic, scholar, and broadcast journalist. He is the author of many books, including Off Mike, Spiritual Envy, and Let There Be Laughter; the co-author of Sound Ideas; and the creator and presenter of the audio lecture series Masterpieces of Short Fiction. He is the host of "The Podcast Conversations With Krasny" and former host of "Forum" on KQED Radio. Organizer: Denise Michaud   A Grownups Member-led Forum program. Forums at the Club are organized and run by volunteer programmers who are members of The Commonwealth Club, and they cover a diverse range of topics. Learn more about our Forums. Learn more about your ad choices. Visit megaphone.fm/adchoices

We're joined by Brad Metzger, President of hospitality recruitment firm Brad Metzger Restaurant Solutions, and Ryan O'Melveny WIlson, the CEO of legendary Los Angeles restaurant group Lawry's, to hear about Chefs Love LA, an unforgettable evening of food and wine, celebrating LA heroes and supporting the restaurant community impacted by the fires. World-famous chefs including Curtis Stone, Jonathan Waxman, Daniel Bouloud, Nyesha Harrington, Jordan Kahn and many many more are all uniting on February 27 for what promises to be a culinary Live Aid happening at Lawry's The Prime Rib in Beverly Hills, with all proceeds benefiting World Central Kitchen and Restaurants Care.  In Part 2, we're joined by a chef who many credit with putting Peruvian food on the map in Los Angeles and beyond, I'm talking about Ricardo Zarate. Ricardo opened the cevicheria known as The Hummbingbird in Echo Park in 2024, and many hailed it as a sort of comeback. But speaking with Ricardo, it's clear that The Hummingbird is a lot more than that. Helpful Links: Chefs Love LA https://www.chefslovela.com/ Brad Metzger Restraurant Solutions https://www.restaurant-solutions.com/ Lawry's https://www.lawrysonline.com/lawrys-the-prime-rib-beverly-hills/ The Hummingbird https://www.instagram.com/thehummingbird.la/?hl=en – Go check out The Lonely Oyster in Echo Park! ⁠https://thelonelyoyster.com/⁠ – Get 10% off at House of Macadamias using code "LAFOOD" https://www.houseofmacadamias.com/pages/la-foods

This is a special episode; not only is it the 90th episode of For Your Listening Pleasure, but this episode is for my Dad. My Dad, Ross Waxman, passed away unexpectedly on November 15, 2024, and today, January 23rd, would have been his 67th birthday. My dad was my biggest cheerleader and unwavering supporter. Whenever I came up with business ideas or creative projects, he backed me 100% without hesitation. One passion project he encouraged me to pursue was creating a podcast dedicated to empathy, diversity, and real people's stories. Initially, the podcast was planned under a different name with two co-hosts, and we conducted practice interviews with family and friends before launching. One of those practice episodes was with my dad, where he shared stories about his life. This unedited conversation is a treasure, capturing his voice and essence, and I feel incredibly fortunate to have it. This recording only shows a glimpse of the amazing person my Dad was. He was truly the coolest person I knew. He always taught me to do the right thing, treat people with respect, help others when I can, and try to live my life with zero regrets. I miss him every day, and I know my life will never be the same without him. I am honored to share a bit of my Dad with you. Please enjoy this meaningful episode. Link to purchase:FYLPxTracee Badway Merch CollaborationFYLPxWRDSMTH Merch Collaboration*suggestion is to size upDownload this episode of For Your Listening Pleasure wherever you get your podcasts! Make sure you follow us on Instagram @foryourlisteningpleasure Click here to listen to the For Your Listening Pleasure Theme Song Playlist on Spotify.To continue the conversation, feel free to DM me at https://www.instagram.com/foryourlisteningpleasure/ or email me at foryourlisteningpleasure@gmail.com.

In this week's episode of Promising Young Surgeon, Dr. Frances Mei Hardin engages in a profound conversation with Dr. Dael Waxman, a physician dedicated to enhancing the well-being of healthcare professionals. The discussion centers around the PERMA model of well-being, exploring how its principles can be applied to foster a flourishing life. Dr. Waxman shares his insights as a physician coach and well-being advocate, drawing from over 30 years of experience in academic family medicine. Together, they delve into the nuances of wellness versus well-being, the concept of flourishing, and practical strategies for cultivating a fulfilling life. 00:00 – Introduction to Dr. Dael Waxman03:40 – Difference Between Wellness and Well Being15:50 – PERMA is About Cultivating Positive Relationships32:47 – A Spirit List37:53 – PERMA Model for Physician Well Being55:10 – Dr. Waxman's Definition of Success Resources:Email Dr. Waxman at dwaxmancoaching.com Dael Waxman MD Coaching & Consultinghttp://www.dwaxmancoaching.com/ Find Dael on Linkedinhttps://www.linkedin.com/in/dael-waxman-md-18917322 Interact with the podcast! Email me at pys@heyinfluent.com to ask questions. We would love to hear from the Promising Young Surgeon audience.Promising Young Surgeon is sponsored by Pattern. Discover why more than 20,000 doctors trust Pattern to shop for disability insurance. Request free quotes in 5 minutes. Compare policies with an expert. Buy with confidence. LINK: https://www.patternlife.com/promising-young-surgeon?campid=349433Subscribe, tune in, and join the conversation as Dr. Hardin and her guests tackle the pressing issues facing today's medical professionals and ponder how to nurture a more compassionate and sustainable healthcare environment. Connect with Frances Mei:https://linktr.ee/francesmei.md https://rethinkingresidency.com/about/ Find More info on this series and other podcasts on the Influent Network at HeyInfluent.comFollow the Influent Network on Social Media:LinkedIn | Twitter (X) | YouTube | TikTok | Instagram | Facebook The Influent Network is where emerging healthcare professionals and esteemed medical experts converge. Our platform is a straightforward resource for career development, financial planning, practice management, and investment insights, designed to foster strong professional connections. Powered by HurrdatSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode looks at the early days of Christmas trees, the origin of glass ornaments, and the practice of mounting lit candles on trees before electric bulbs were invented. Research: · “36 Perish as Party Guests Stampede to Flee Flames.” The Minneapolis Star. Dec 25, 1924. https://www.newspapers.com/image/178762039/ · “Accident From a Christmas Tree.” The Morning Post. Jan 11, 1850. https://www.newspapers.com/image/402121758/?match=1&terms=%22christmas%20tree%22%20Victoria · Barnes, Allison. “The First Christmas Tree. History Today. December 12, 2006. https://www.historytoday.com/archive/history-matters/first-christmas-tree · Brittain, J. E. "John R. Crouse and the Society for Electrical Development [Scanning the Past]." Proceedings of the IEEE, vol. 86, no. 12, pp. 2475-2477, Dec. 1998. https://ieeexplore.ieee.org/document/735455 · Britannica, The Editors of Encyclopaedia. "Woolworth Co.." Encyclopedia Britannica, 30 Nov. 2024, https://www.britannica.com/money/Woolworth-Co · “A Christmas tree candle set fire … “ The Jersey City News. Jan. 9, 1892. https://www.newspapers.com/image/856106974/?match=1&terms=christmas%20tree%20candles%20fire · Coleridge, Samuel Taylor, and Ernest Hartley Coleridge, ed. “LETTERS OFSAMUEL TAYLOR COLERIDGE.” London. William Heinemann. 1895. Accessed online: https://gutenberg.org/files/44553/44553-h/44553-h.htm · Flander, Judith. “Christmas: A Biography.” Thomas Dunne Books. 2017. · Foyle, Jonathan. “The Business of Baubles – and the Town That Invented Them.” Financial Times. Dec. 19, 2014. https://www.ft.com/content/ce33a468-812a-11e4-b956-00144feabdc0 · “Glass Christmas Ornaments.” The German Way. https://www.german-way.com/history-and-culture/holidays-and-celebrations/christmas/glass-christmas-ornaments/ · Loud, Nicholas. “The History of Christmas Decorations in America.” Saturday Evening Post. December 2020. https://www.saturdayeveningpost.com/2020/12/the-history-of-christmas-decorations-in-america/ · Lorch, Mark. “The Forgotten Scientist Who Made Modern Christmas Ornaments Possible.” Fast Company. Dec. 21, 2021. https://www.fastcompany.com/90707875/the-forgotten-scientist-who-made-modern-christmas-ornaments-possible · Malanowski, Jamie. “Untangling the History of Christmas Lights.” Smithsonian. December 2016. https://www.smithsonianmag.com/history/untangling-history-christmas-lights-180961140/ · “No Christmas Tree Fires Are Reported Here.” Alton Evening Telegraph. Dec. 28. 1921. https://www.newspapers.com/image/19919324/?match=1&terms=christmas%20tree%20candles%20fire · “A few years ago the caution …” Daily Plainsman. Dec. 12, 1929. https://www.newspapers.com/image/23432095/?match=1&terms=christmas%20tree%20candles%20fire · “Christmas Tree Candles – Fire.” The Courier-Journal of Louisville. Jan. 05, 1909. https://www.newspapers.com/image/119330231/?match=1&terms=christmas%20tree%20candles%20fire · “The Christmas Tree at Windsor Castle.” The Morning Post. Dec. 28, 1848. https://www.newspapers.com/image/402196932/?match=1&terms=%22christmas%20tree%22%20Victoria · “Feiker Takes Commerce Post.” New York Times. July 2, 1931. https://timesmachine.nytimes.com/timesmachine/1931/07/02/113339929.pdf?pdf_redirect=true&ip=0 · “German Hospital, Dalston.” The Morning Post. Jan. 1, 1848. https://www.newspapers.com/image/402129709/?match=1&terms=%22christmas%20tree%22%20Victoria · Prior, Dr. M. Faye. “Trimming the Tree – Glass and metal Christmas tree decorations.” York Museum Trust. https://www.yorkmuseumstrust.org.uk/blog/trimming-the-tree-glass-and-metal-christmas-tree-decorations/ · Roberts, Sam. “Si Spiegel, War Hero Who Modernized Christmas Trees, Dies at 99.” New York Times. Feb. 11, 2024. · Scinto, Madeleine. “Americans Are Spending A Whopping $6 Billion On Christmas Decorations This Year.” Business Insider. Dec. 7, 2011. https://www.businessinsider.com/americans-are-spending-a-record-6-billion-on-christmas-decorations-2011-12 · Shapiro, Laurie Gwen. “He Bombed the Nazis, Outwitted the Soviets and Modernized Christmas.” New York Times. Dec. 17, 2021. https://www.nytimes.com/2021/12/17/nyregion/bomber-pilot-christmas-trees.html · Tikkanen, Amy. "How Did the Tradition of Christmas Trees Start? ". Encyclopedia Britannica, 2 Dec. 2022, https://www.britannica.com/story/how-did-the-tradition-of-christmas-trees-start · Waxman, Olivia B. “How Christmas Trees Became a Holiday Tradition.” TIME. Dec. 21, 2020. https://time.com/5736523/history-of-christmas-trees/ · Waxman, Olivia B. “The Electricity Lobby Was Behind the First National Christmas Tree Lighting.” TIME. Dec. 1, 2016. https://time.com/4580764/national-christmas-tree-lighting-history-origins/ · Waxman, Olivia B. “This Was the First Rockefeller Center Christmas Tree.” TIME. Nov. 30, 2016. https://time.com/4578685/first-rockefeller-center-christmas-tree-lighting/ See omnystudio.com/listener for privacy information.

This episode is sponsored by Eden Beit Shemesh. Contact Rina Weinberg at info@edenbeitshemesh.com for more details.In this episode of the 18Forty Podcast, we talk to a panel of rabbis about yeshiva, seminary, and the “year in Israel.” Additionally, we hear from Dov Rosenblatt, who more than two decades ago wrote the satirical song “Flippin' Out.” Gap-year programs have become one of the primary points of contact that American Jews have with Israel. But, paradoxically, the year in Israel is a quintessentially American experience. In this episode we discuss:What are the signs of a healthy gap-year experience? How can gap-year programs become more focused on Israel? How has the year in Israel changed in a post–October 7 world?Tune in to hear a conversation about how the gap year can meet the needs of this generation.Interview with Dov Rosenblatt begins at 16:25.Shaalvim Dinner panel with Ari Waxman, Judah Mischel, and Gershon Turetsky begins at 33:36.References:“Flippin' Out” by Blue FringeFlipping Out? Myth or Fact? The Impact of the "Year in Israel" by Shalom Z. Berger, Daniel Jacobson, Chaim I. Waxman“Why Space Tourists Won't Find the Awe They Seek” by Henry Wismayer18Forty Podcast: “Rav Judah Mischel: A Change in Progress”“‘Dumbed-Down Catholicism Was a Disaster'” by Molly WorthenBecome a supporter of this podcast: https://www.spreaker.com/podcast/18forty-podcast--4344730/support.

Vlad Sedler and Jason Anthony are joined by the best fantasy baseball player in the world, Phil Dussault. The trio break down the first NFBC 12-team OC of the fantasy season that both Phil and Vlad were in. This episode went off outline, covering a variety of interesting topics related to early draft strategy, player analysis, roster construction, and assessing market value. If you love talking about fantasy baseball year-round, this episode is for you. It's also guaranteed to immediately bolster your fantasy baseball IQ.Topics Discussed: Drafting before setting our own projections and rankingsThe early OC with Vlad and Phil (a Waxman sandwich)Avoiding biases from setting in (aka, Pfaadtology)The early catcher strategyPlaying time for the young CardinalsSurf or Turf for TON in TorontoCorrea vs. the MI fieldGladiator closers vs. DC closers (not a Marvel movie)Pivetta or Flaherty on the NationalsJordan Romano is big mad, but is he healthy?The Rays have 27 starting pitchers going 3-4 innings each"Why draft Reliever X in Round 10 when you can draft Reliever Y in Round 45" - The Robot

A weekly podcast of progressive and uplifting Pure Trance music, presented by Solarstone. 01. Waxman (CA) - Better Days [Pure Progressive]02. Leon Lobato, axman (CA) - Distant Horizons [Elevated]03. Gonza Rodriguez - Obsidian (James Beetham's Angelic Remix) [Massive Harmony]04. axman (CA), Will RP Melville - Here We Are (Forerunners Remix) [Pure Progressive]05. Floating Points - Del Oro [Ninja Tune]06. axman (CA) - Get What You Want (Club Mix) [Manual Music]07. axman (CA) - Don't Hurt Me [Ugenius]08. Eli & Fur - Night Blooming Jasmine (Rodriguez Jr. Remix) [Anjunadeep]09. Gai Barone, Giancly Nativo - Via Fermi [Music To Die For]10. Amtrak - Arc On The Range [Openers] 11. Juno Mamba - Undercut [Soothsayer]

There is much debate among academics and policy experts over the power the Constitution affords to the president and Congress to initiate military conflicts. But as Michael Ramsey and Matthew Waxman, law professors at the University of San Diego and Columbia, respectively, point out in a recent law review article, this focus misses the mark. In fact, the most salient constitutional war powers question—in our current era dominated by authorizations for the use of military force—is not whether the president has the unilateral authority to start large-scale conflicts. Rather, it is the scope of Congress's authority to delegate its war-initiation power to the president. This question is particularly timely as the Supreme Court appears growingly skeptical of significant delegations of congressional power to the executive branch.Matt Gluck, Research Fellow at Lawfare, spoke with Waxman and Ramsey about their article. They discussed the authors' findings about the history of war power delegations from the Founding era to the present, what these findings might mean if Congress takes a more assertive role in the war powers context, and why these constitutional questions matter if courts are likely to be hesitant to rule on war powers delegation questions.Support this show http://supporter.acast.com/lawfare. Hosted on Acast. See acast.com/privacy for more information.